Still, in a retrospective multicenter cohort study with 141 mild COVID-19 patients by Xu et al. (342), the arbidol/IFN-α2b combination proved more effective in accelerating pneumonia recovery than IFN-α2b monotherapy, but this was not the case for viral clearance or reducing the length of hospital stay than IFN-α2b monotherapy.